Runben Biotechnology (SH:603193) Zheng Quan Zhi Xing·2025-05-22 10:28Core Viewpoint - The legal opinion confirms that the convening and conducting of the 2025 first extraordinary general meeting of shareholders by Runben Biotechnology Co., Ltd. complies with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][6]. Group 1: Meeting Procedures - The extraordinary general meeting was convened by the company's second board of directors based on a resolution from the eighth meeting held on May 6, 2025 [2][3]. - The meeting was held on May 22, 2025, at 15:30 in Guangzhou, and was presided over by the chairman Zhao Guiqin [2][3]. - The meeting's notice included details about the equity registration date, voting methods, and contact information, which were all in accordance with legal requirements [2][4]. Group 2: Attendance and Voting - A total of 6 shareholders and their representatives attended the meeting, holding shares registered with the Shanghai Stock Exchange as of the equity registration date of May 16, 2025 [3][4]. - Shareholders had the option to vote either in person or via an online voting platform provided by the Shanghai Stock Exchange, with specific time frames for each voting method [4][5]. - The online voting was validated by the Shanghai Stock Exchange system, and a total of 88 shareholders participated in online voting, representing 24,077,575 shares, which is 5.9510% of the total share capital [5]. Group 3: Resolutions Passed - The meeting adopted the proposal regarding the signing of the input-output regulatory agreement and external investment, with the voting results being consistent with the matters announced in the meeting notice [5][6]. - The voting process combined both in-person and online votes, ensuring that all votes were counted and reported accurately [6]. - The resolutions passed during the meeting were deemed legal and valid, adhering to the company's articles of association and relevant laws [6].